Invesco Biotechnology & Genome ETF PBE
Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed
- Expense ratio
- 0.58%
- Net assets
- $281.9M
- Holdings
- 33
- 12-month distribution yield
- 1.34%
- Asset class
- Equity
Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund listed on NYSE Arca in the United States, issued by Invesco. Its category is Equity · US (equity). Its last price was US$99.22 on 20 Oct 2026. Its expense ratio is 0.58% a year, from its prospectus dated 28 Aug 2025. It reported net assets of US$281.95 million as of 31 Jul 2026. Its latest holdings report lists 33 holdings as of 31 Jul 2026. Over the last 12 months it paid distributions of US$1.33 a unit, a 12-month distribution yield of 1.34%, paid quarterly.
Fees
- Total annual operating expenses (gross)
- 0.58%
- Net, after fee waivers or reimbursements
- No waiver stated
- Management fee
- 0.50%
- Prospectus date
- 28 Aug 2025
- Filed with the SEC
- 27 Aug 2025
Size and reporting
- Net assets
- $281,946,188
- Total assets
- $332,656,191
- Holdings as of
- 31 Jul 2026
- Report made public
- 28 Sep 2026 (59 days after the month end)
Top holdings
Largest 25 of 33 positions, as of 31 Jul 2026. Weight is the percent of net assets the fund reported.
| # | Holding | Identifier | Weight | Value (USD) | Type | Country | Currency |
|---|---|---|---|---|---|---|---|
| 1 | Invesco Private Prime Fund | No identifier reported | 12.89% | $36.3M | Short-term investment vehicles (cash funds) | United States | USD |
| 2 | Regeneron Pharmaceuticals, Inc. | US75886F1075 | 5.47% | $15.4M | Equity (common) | United States | USD |
| 3 | Amgen Inc. | US0311621009 | 5.22% | $14.7M | Equity (common) | United States | USD |
| 4 | CareDx, Inc. | US14167L1035 | 5.04% | $14.2M | Equity (common) | United States | USD |
| 5 | Vertex Pharmaceuticals Inc. | US92532F1003 | 4.99% | $14.1M | Equity (common) | United States | USD |
| 6 | Invesco Private Government Fund | No identifier reported | 4.97% | $14.0M | Short-term investment vehicles (cash funds) | United States | USD |
| 7 | Royalty Pharma PLC Royalty Pharma PLC, Class A | GB00BMVP7Y09 | 4.94% | $13.9M | Equity (common) | United Kingdom | USD |
| 8 | Biogen Inc. | US09062X1037 | 4.79% | $13.5M | Equity (common) | United States | USD |
| 9 | Gilead Sciences, Inc. | US3755581036 | 4.43% | $12.5M | Equity (common) | United States | USD |
| 10 | United Therapeutics Corp. | US91307C1027 | 4.08% | $11.5M | Equity (common) | United States | USD |
| 11 | Bio-Techne Corp. | US09073M1045 | 3.73% | $10.5M | Equity (common) | United States | USD |
| 12 | Illumina, Inc. | US4523271090 | 3.51% | $9.9M | Equity (common) | United States | USD |
| 13 | Protagonist Therapeutics, Inc. | US74366E1029 | 3.40% | $9.6M | Equity (common) | United States | USD |
| 14 | Vericel Corp. | US92346J1088 | 3.27% | $9.2M | Equity (common) | United States | USD |
| 15 | Alnylam Pharmaceuticals, Inc. | US02043Q1076 | 3.17% | $8.9M | Equity (common) | United States | USD |
| 16 | Incyte Corp. | US45337C1027 | 3.06% | $8.6M | Equity (common) | United States | USD |
| 17 | Repligen Corp. | US7599161095 | 3.04% | $8.6M | Equity (common) | United States | USD |
| 18 | Acadia Pharmaceuticals Inc. | US0042251084 | 3.02% | $8.5M | Equity (common) | United States | USD |
| 19 | Halozyme Therapeutics, Inc. | US40637H1095 | 2.98% | $8.4M | Equity (common) | United States | USD |
| 20 | Qiagen N.V. | NL0015002SN0 | 2.89% | $8.2M | Equity (common) | Netherlands | USD |
| 21 | BioMarin Pharmaceutical Inc. | US09061G1013 | 2.82% | $8.0M | Equity (common) | United States | USD |
| 22 | Neurocrine Biosciences, Inc. | US64125C1099 | 2.66% | $7.5M | Equity (common) | United States | USD |
| 23 | Exelixis, Inc. | US30161Q1040 | 2.64% | $7.4M | Equity (common) | United States | USD |
| 24 | BioCryst Pharmaceuticals, Inc. | US09058V1035 | 2.63% | $7.4M | Equity (common) | United States | USD |
| 25 | Veracyte, Inc. | US92337F1075 | 2.60% | $7.3M | Equity (common) | United States | USD |
Breakdowns
Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.
Asset type
| Type | Weight | Bar |
|---|---|---|
| Equity (common) | 100.05% | |
| Short-term investment vehicles (cash funds) | 17.93% |
Country
| Country | Weight | Bar |
|---|---|---|
| United States | 108.58% | |
| United Kingdom | 4.94% | |
| Netherlands | 2.89% | |
| Cayman Islands | 1.56% |
Currency exposure
| Currency | Weight | Bar |
|---|---|---|
| US dollar (USD) | 117.98% |
Sector
| Sector | Weight | Bar |
|---|---|---|
| Health Care | 74.90% |
Source: SEC Form N-PORT (opens in a new tab) Holdings as of
Distributions
- Paid in the last 12 months
- $1.3320
- 12-month yield
- 1.34%
- Frequency
- Quarterly
- Latest ex-date
- 21 Sep 2026
12-month yield = distributions per unit with an ex-date in the last 12 months ($1.3320) ÷ latest price ($99.22) × 100 = 1.34%. It looks back, so it is not a forecast; special distributions in the window are included.
Why a distribution yield is not the fund's return: yield vs total return
Distribution history table (10 payments)
| Ex-date | Amount per unit |
|---|---|
| 21 Sep 2026 | $0.0190 |
| 22 Jun 2026 | $0.8110 |
| 23 Mar 2026 | $0.0820 |
| 22 Dec 2025 | $0.4200 |
| 22 Sep 2025 | $0.2340 |
| 23 Jun 2025 | $0.1300 |
| 24 Mar 2025 | $0.0340 |
| 24 Jun 2024 | $0.0080 |
| 18 Mar 2024 | $0.0240 |
| 20 Jun 2023 | $0.0140 |
Filings and sources
- Form N-PORT report for July 2026 (opens in a new tab)
- Prospectus filing with the fee table (opens in a new tab)
- All SEC filings for this fund series (S000003026) (opens in a new tab)
- Nasdaq Trader symbol directory (opens in a new tab)
- Yahoo Finance quote and distributions (opens in a new tab)
- How the ETF figures are collected
Compare with
Largest funds in the same category:
- PBE and VTI Vanguard Morningstar Total Stock Market ETF
- PBE and VOO Vanguard S&P 500 ETF
- PBE and IVV iShares Core S&P 500 ETF
- PBE and QQQ Invesco QQQ Trust, Series 1